Database Query Results : Chrysin, ,

CHr, Chrysin: Click to Expand ⟱
Features:
Chrysin is found in passion flower and honey. It is a flavonoid.
-To reach plasma levels that might more closely match the concentrations used in in vitro studies (typically micromolar), considerably high doses or advanced delivery mechanisms would be necessary.
Chrysin is widely summarized as modulating PI3K/Akt and MAPK pathways in cancer.

-Note half-life 2 hrs, BioAv very poor often <1%
Pathways:
Graphical Pathways

- may induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- May Lower AntiOxidant defense in Cancer Cells: NRF2↓, GSH↓ HO1↓
- May Raise AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, TIMP2, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, P53↑, HSP↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, cMyc↓, GLUT1↓, LDH↓, HK2↓, PDKs↓, HK2↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, AMPK↓, ERK↓, JNK, TrxR,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 PI3K → AKT (± mTOR) survival axis ↓ PI3K/AKT (often ↓ p-AKT; downstream growth signals ↓) ↔ R, G Growth/survival suppression Frequently reported hub effect; contributes to reduced proliferation and sensitization to stress/apoptosis programs.
2 Intrinsic apoptosis (p53/Bcl-2 family → caspase-9/3) ↑ p53 axis (context); Bax↑/Bcl-2↓; ↑ caspase-9/3; apoptosis ↑ ↔ (generally less activation) G Apoptosis execution Common endpoint across many tumor models; often downstream of survival-pathway suppression and stress signaling.
3 ER stress / UPR (PERK and related arms) ER stress ↑; UPR activation ↑ ↔ R, G Stress-to-death coupling ER stress has been directly shown in chrysin-treated cancer cells and can couple to apoptosis.
4 JAK / STAT3 signaling ↓ STAT3 signaling (context) ↔ R, G Anti-survival transcription STAT3 inhibition is reported in cancer models and often aligns with reduced proliferation and increased apoptosis.
5 ROS / oxidative stress (context-dependent) ROS modulation (often ↑ mitochondrial ROS in tumor models) ↔ / antioxidant behavior in some contexts P, R, G Stress amplifier (variable) Direction depends on dose/model; avoid absolute “ROS always ↑/↓”. Oxidative stress + DDR has been linked to anti-angiogenic effects in vivo in melanoma models.
6 MAPK re-wiring (ERK / JNK / p38) MAPK shifts; JNK/p38 often stress-activated; ERK variable ↔ P, R, G Signal reprogramming MAPK effects differ by cell line; chrysin can suppress JNK/ERK signaling to reduce MMP-9 in some models.
7 Cell-cycle arrest / proliferation control Cell-cycle arrest ↑; proliferation ↓ ↔ G Cytostasis Often observed as later phenotype-level outcomes, downstream of signaling changes.
8 Invasion / metastasis (MMP-9; EMT programs) MMP-9 ↓; migration/invasion ↓ (context) ↔ G Anti-invasive phenotype Chrysin can reduce MMP-9 expression via AP-1 suppression and MAPK pathway effects in certain cancer models.
9 Angiogenesis (VEGF/angiogenic outputs) Angiogenesis outputs ↓ (context) ↔ G Anti-angiogenic support In melanoma models, chrysin has been associated with angiogenesis regression linked to oxidative stress and DNA damage response.
10 Bioavailability constraint (oral PK limitation) Systemic exposure often low without formulation — — Translation constraint Native chrysin oral bioavailability is extremely low due to poor solubility and extensive glucuronidation/sulfation with efflux; formulation strategies are commonly required for systemic effects.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/physical–chemical effects; rapid signaling / phosphorylation shifts)
  • R: 30 min–3 hr (acute stress-response and redox signaling)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
Scientific Papers found: Click to Expand⟱
2800- CHr,    Chrysin Activates Notch1 Signaling and Suppresses Tumor Growth of Anaplastic Thyroid Carcinoma In vitro and In vivo
- in-vitro, Thyroid, NA
TumCG↓, NOTCH↑, cl‑PARP↑, Apoptosis↑,
2790- CHr,    Chrysin: Pharmacological and therapeutic properties
- Review, Var, NA
*hepatoP↑, *neuroP↓, *ROS↓, *cardioP↑, *Inflam↓, eff↑, hTERT/TERT↓, cycD1/CCND1↓, MMP9↓, MMP2↓, TIMP1↑, TIMP2↑, BioAv↑, HK2↓, ROS↑, MMP↓, Casp3↑, ADP:ATP↑, Apoptosis↑, ER Stress↑, UPR↑, GRP78/BiP↝, eff↑, Ca+2↑,
2791- CHr,    Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction
- in-vitro, Ovarian, OV90
TumCP↓, TumCD↑, ROS↑, Ca+2↑, MMP↓, MAPK↑, PI3K↑, p‑Akt↑, PCNA↓, p‑p70S6↑, p‑ERK↑, p38↑, JNK↑, DNAdam↑, TumCCA↑, chemoP↑,
2792- CHr,    Chrysin induces death of prostate cancer cells by inducing ROS and ER stress
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
DNAdam↑, TumCCA↑, MMP↓, ROS↑, lipid-P↑, ER Stress↑, UPR↑, PERK↑, eIF2α↑, GRP78/BiP↑, PI3K↓, Akt↓, p70S6↓, MAPK↑,
2793- CHr,    Chrysin Inhibits TAMs-Mediated Autophagy Activation via CDK1/ULK1 Pathway and Reverses TAMs-Mediated Growth-Promoting Effects in Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H157 - in-vivo, NA, NA
TumCG↓, M2 MC↑, CDK1↓,
2794- CHr,    An updated review on the versatile role of chrysin in neurological diseases: Chemistry, pharmacology, and drug delivery approaches
- Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *IL1β↓, *TNF-α↓, *COX2↓, *iNOS↓, *NF-kB↓, *JNK↓, *HDAC↓, *GSK‐3β↓, *IFN-γ↓, *IL17↓, *GSH↑, *NRF2↑, *HO-1↑, *SOD↑, *MDA↓, *NO↓, *GPx↑, *TBARS↓, *AChE↓, *GR↑, *Catalase↑, *VitC↑, *memory↑, *lipid-P↓, *ROS↓,
2795- CHr,    Combination of chrysin and cisplatin promotes the apoptosis of Hep G2 cells by up-regulating p53
- in-vitro, Liver, HepG2
ChemoSen↑, P53↑, ERK↑, BAX↑, DR5↑, Bcl-2↓, Casp8↑, Cyt‑c↑, Casp9↑,
2796- CHr,    Chemopreventive effect of chrysin, a dietary flavone against benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice
- in-vivo, Lung, NA
PCNA↓, COX2↓, NF-kB↓, chemoPv↑, *SOD↑, *Catalase↓, *GR↓, *GPx↓, *lipid-P↓, *COX2↓, *NF-kB↓, *ROS↓,
2797- CHr,    A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells
- in-vivo, BC, NA - in-vitro, BC, 4T1
tumCV↓, p‑STAT3↓, VEGF↓, Weight∅, angioG↓,
2798- CHr,    Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
HDAC↓, HDAC8↓, TumCG↓, Diff↑,
2799- CHr,    Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB
- in-vivo, RCC, NA
*chemoPv↑, *ROS↓, *Inflam↓,
953- CHr,    Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization
- in-vivo, NA, NA
Hif1a↓, VEGF↓,
2801- CHr,    AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells
- in-vitro, Lung, A549
AMPK↑, Akt↓, ChemoSen↑, ROS↑,
2802- CHr,    Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis
- in-vitro, Pca, DU145 - in-vivo, Pca, NA
Hif1a↓, VEGF↓, angioG↓,
2803- CHr,  5-FU,    Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells
- in-vitro, GC, AGS
ChemoSen↑, TumCCA↑, eff↑, MDR1↓,
2804- CHr,  Rad,    Gamma-Irradiated Chrysin Improves Anticancer Activity in HT-29 Colon Cancer Cells Through Mitochondria-Related Pathway
- in-vitro, CRC, HT29
RadioS↑, ROS↑, MMP↓, Casp3↑, Casp9↑, cl‑PARP↑,
2805- CHr,    Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC)
- in-vitro, ESCC, KYSE150 - in-vivo, ESCC, NA
FAK↓, GlucoseCon↓, Casp3↑, Casp7↑, p‑Akt↓, TumCG↓, Weight∅,
2806- CHr,  Se,    Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy
- in-vitro, Var, NA
eff↑, selectivity↑, Dose↝, TrxR↓, GSH↓, MMP↓, ROS↑, H2O2↑,
2807- CHr,    Evidence-based mechanistic role of chrysin towards protection of cardiac hypertrophy and fibrosis in rats
- in-vivo, Nor, NA
*antiOx↑, Inflam↓, *cardioP↑, *GSH↑, *SOD↑, *Catalase↑, *GAPDH↑, *BAX↓, *Bcl-2↑, *PARP↓, *Cyt‑c↓, *Casp3↓, *NOX4↓, *NRF2↑, *HO-1↑, *HSP70/HSPA5↑,
3258- CHr,  PBG,    Chrysin Induced Cell Apoptosis and Inhibited Invasion Through Regulation of TET1 Expression in Gastric Cancer Cells
- in-vitro, GC, MKN45
TET1↑, Apoptosis↑, TumCI↓, TumCMig↓,
4260- CHr,    Chrysin modulates the BDNF/TrkB/AKT/Creb neuroplasticity signaling pathway: Acting in the improvement of cognitive flexibility and declarative, working and aversive memory deficits caused by hypothyroidism in C57BL/6 female mice
- in-vivo, NA, NA
*BDNF↑, *TrkB↑, *Akt↑, *CREB↑, *memory↑, *cognitive↑,
2788- CHr,    Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action
- Review, Var, NA
*neuroP↑, *Inflam↓, *ROS↓, NF-kB↓, *PCNA↓, *COX2↓, ChemoSen↑, Hif1a↓, angioG↓, *chemoPv↑, PDGF↓, *memory↑, *RenoP↑, *PPARα↑, *lipidLev↓, *hepatoP↑, *cardioP⇅, *BioAv↓,
1033- CHr,    Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression
- vitro+vivo, HCC, NA
TumCG↓, CD4+↑, CD8+↑, PD-L1↓,
1107- CHr,    Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway
- in-vitro, BC, NA
TumCP↓, Apoptosis↑, MMP-10↓, E-cadherin↑, Vim↓, Snail↓, Slug↓, EMT↓,
1143- CHr,    Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2
- in-vitro, HCC, HepG2 - in-vivo, NA, NA - in-vitro, HCC, HepG3 - in-vitro, HCC, HUH7
HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, Apoptosis↑,
1144- CHr,    8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK
- in-vitro, HCC, HepG2 - in-vitro, HCC, Bel-7402 - in-vitro, Nor, HL7702
Casp3↑, *ROS∅, ROS↑, JNK↑, *toxicity↓,
1145- CHr,    Chrysin inhibits propagation of HeLa cells by attenuating cell survival and inducing apoptotic pathways
- in-vitro, Cerv, HeLa
tumCV↓, BAX↑, BID↑, BOK↑, APAF1↑, TNF-α↑, FasL↑, Fas↑, FADD↑, Casp3↑, Casp7↑, Casp8↑, Casp9↑, Mcl-1↓, NAIP↓, Bcl-2↓, CDK4↓, CycB/CCNB1↓, cycD1/CCND1↓, cycE1↓, TRAIL↑, p‑Akt↓, Akt↓, mTOR↓, PDK1↓, BAD↓, GSK‐3β↑, AMPK↑, p27↑, P53↑,
1249- CHr,    Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes
- in-vitro, CLL, NA
ROS↑, MMP↓, ADP:ATP↑, Casp3↑, Apoptosis↑,
2590- CHr,    Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway
- in-vitro, GBM, T98G - in-vitro, GBM, U251 - in-vitro, GBM, U87MG
TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,
2591- CHr,  doxoR,    Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑, HO-1↓,
2780- CHr,    Anti-cancer Activity of Chrysin in Cancer Therapy: a Systematic Review
- Review, Var, NA
*antiOx↑, Inflam↓, *hepatoP↑, AntiCan↑, Cyt‑c↑, Casp3↑, XIAP↓, p‑Akt↓, PI3K↑, Apoptosis↑, COX2↓, FAK↓, AMPK↑, STAT3↑, MMP↓, DNAdam↑, BAX↑, Bak↑, Casp9↑, p38↑, MAPK↑, TumCCA↑, ChemoSen↑, HDAC8↓, Wnt↓, NF-kB↓, angioG↓, BioAv↓,
2781- CHr,  PBG,    Chrysin a promising anticancer agent: recent perspectives
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, MMP9↑, uPA↓, VEGF↓, AR↓, Casp↑, TumMeta↓, TumCCA↑, angioG↓, BioAv↓, *hepatoP↑, *neuroP↑, *SOD↑, *GPx↑, *ROS↓, *Inflam↓, *Catalase↑, *MDA↓, ROS↓, BBB↑, Half-Life↓, BioAv↑, ROS↑, eff↑, ROS↑, ROS↑, lipid-P↑, ER Stress↑, NOTCH1↑, NRF2↓, p‑FAK↓, Rho↓, PCNA↓, COX2↓, NF-kB↓, PDK1↓, PDK3↑, GLUT1↓, Glycolysis↓, mt-ATP↓, Ki-67↓, cMyc↓, ROCK1↓, TOP1↓, TNF-α↓, IL1β↓, CycB/CCNB1↓, CDK2↓, EMT↓, STAT3↓, PD-L1↓, IL2↑,
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,
2783- CHr,    Apoptotic Effects of Chrysin in Human Cancer Cell Lines
- Review, Var, NA
TumCP↓, Apoptosis↑, Casp↑, PCNA↓, p38↑, NF-kB↑, DNAdam↑, XIAP↓, Cyt‑c↑, Casp3↑, Akt↓, SCF↓, hTERT/TERT↓, COX2↓, *Inflam↓, *antiOx↑, *chemoPv↑, AR-V7?, CYP19?,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
2786- CHr,    Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives
- Review, Var, NA
Apoptosis↑, TumCCA↑, angioG↓, TumCI↓, TumMeta↑, *toxicity↓, selectivity↑, chemoPv↑, *GSTs↑, *NADPH↑, *GSH↑, HDAC8↓, Hif1a↓, *ROS↓, *NF-kB↓, SCF↓, cl‑PARP↑, survivin↓, XIAP↓, Casp3↑, Casp9↑, GSH↓, ChemoSen↑, Fenton↑, P21↑, P53↑, cycD1/CCND1↓, CDK2↓, STAT3↓, VEGF↓, Akt↓, NRF2↓,
2787- CHr,    Network pharmacology unveils the intricate molecular landscape of Chrysin in breast cancer therapeutics
- Analysis, Var, MCF-7
TumCP↓, angioG↓, TumCI↓, TumMeta↓, TP53↑, Akt↓, Casp3↑, tumCV↓, TNF-α↓, BioAv↑, BioAv↑, AKT1↓,
2789- CHr,    Anticancer Activity of Ether Derivatives of Chrysin
- Review, Var, NA
eff↑, COX2↓, PGE2↓, eff↑,
481- CUR,  CHr,  Api,    Flavonoid-induced glutathione depletion: Potential implications for cancer treatment
- in-vitro, Liver, A549 - in-vitro, Pca, PC3 - in-vitro, AML, HL-60
GSH↓, mtDam↑, MMP↓, Cyt‑c↑,
1084- LT,  CHr,    Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells
- in-vitro, Nor, RAW264.7
*COX2↓, *COX2∅, *PGE2↓, *ROS↓,
4883- LT,  CHr,  BRU,  VitC,    An update of Nrf2 activators and inhibitors in cancer prevention/promotion
- Review, Var, NA
*NRF2↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 42

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   GSH↓, 3,   H2O2↑, 1,   HO-1↓, 3,   lipid-P↑, 3,   NRF2↓, 6,   ROS↓, 1,   ROS↑, 14,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 2,   mt-ATP↓, 1,   BOK↑, 1,   MMP↓, 10,   MMP↑, 1,   mtDam↑, 1,   XIAP↓, 4,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   ALAT↓, 1,   AMPK↑, 3,   cMyc↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 3,   HK2↓, 5,   lactateProd↓, 2,   LDH↓, 1,   LDL↓, 1,   NADPH↓, 1,   PDK1↓, 3,   PDK3↑, 1,   PPARα↓, 1,  

Cell Death ⓘ

Akt↓, 8,   p‑Akt↓, 3,   p‑Akt↑, 1,   APAF1↑, 1,   Apoptosis↑, 11,   BAD↓, 1,   Bak↑, 1,   BAX↑, 4,   Bcl-2↓, 2,   Bcl-xL↓, 1,   BID↑, 1,   Casp↑, 2,   Casp3↑, 12,   Casp7↑, 2,   Casp8↑, 2,   Casp9↑, 6,   Cyt‑c↑, 6,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   hTERT/TERT↓, 5,   iNOS↓, 1,   JNK↑, 2,   MAPK↑, 3,   Mcl-1↓, 2,   NAIP↓, 1,   p27↑, 1,   p38↑, 3,   survivin↓, 1,   TRAIL↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p70S6↓, 1,   p‑p70S6↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 2,   p‑eIF2α↑, 1,   ER Stress↑, 5,   GRP78/BiP↑, 2,   GRP78/BiP↝, 1,   PERK↑, 2,   UPR↑, 4,   XBP-1↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 5,   P53↑, 3,   PARP↑, 1,   cl‑PARP↑, 3,   PCNA↓, 5,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 3,   CDK4↓, 2,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 6,   cycE1↓, 1,   P21↑, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

AR-V7?, 1,   Diff↑, 1,   EMT↓, 5,   ERK↓, 2,   ERK↑, 1,   p‑ERK↑, 1,   GSK‐3β↑, 1,   HDAC↓, 3,   HDAC8↓, 3,   Let-7↑, 1,   mTOR↓, 3,   NOTCH↑, 1,   NOTCH1↑, 3,   PI3K↓, 2,   PI3K↑, 2,   SCF↓, 2,   SHP1↑, 1,   STAT3↓, 3,   STAT3↑, 1,   p‑STAT3↓, 2,   p‑STAT3↑, 1,   TOP1↓, 2,   TumCG↓, 5,   Wnt↓, 1,  

Migration ⓘ

Ca+2↑, 5,   CDKN1C↑, 1,   CLDN1↓, 2,   E-cadherin↑, 4,   FAK↓, 2,   p‑FAK↓, 1,   Fibronectin↓, 1,   Ki-67↓, 1,   MMP-10↓, 2,   MMP2↓, 3,   MMP9↓, 3,   MMP9↑, 1,   N-cadherin↓, 1,   PDGF↓, 1,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 2,   Snail↓, 2,   TET1↑, 3,   TIMP1↑, 1,   TIMP2↑, 1,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 6,   TumMeta↓, 3,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 8,   ATF4↑, 1,   EGFR↓, 1,   Hif1a↓, 5,   VEGF↓, 7,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX2↓, 6,   COX2↑, 1,   IL10↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 2,   Inflam↓, 2,   M2 MC↑, 1,   NF-kB↓, 5,   NF-kB↑, 1,   PD-L1↓, 2,   PGE2↓, 2,   TLR4↓, 1,   TNF-α↓, 3,   TNF-α↑, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   CYP19?, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 6,   ChemoSen↑, 8,   Dose↝, 2,   eff↑, 15,   Half-Life↓, 1,   MDR1↓, 1,   RadioS↑, 2,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 1,   EGFR↓, 1,   hTERT/TERT↓, 5,   IL6↓, 2,   Ki-67↓, 1,   LDH↓, 1,   PD-L1↓, 2,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 2,   neuroP↑, 2,   OS↑, 1,   RenoP↑, 1,   TumVol↓, 1,   Weight∅, 2,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 194

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↓, 1,   Catalase↑, 4,   GPx↓, 1,   GPx↑, 2,   GSH↑, 3,   GSTs↑, 2,   HDL↑, 1,   HO-1↑, 2,   lipid-P↓, 2,   MDA↓, 2,   NOX4↓, 1,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 11,   ROS∅, 1,   SOD↑, 5,   TBARS↓, 1,   VitC↑, 1,  

Core Metabolism/Glycolysis ⓘ

CREB↑, 1,   GAPDH↑, 1,   lipidLev↓, 2,   NADPH↑, 1,   PPARα↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Akt↑, 1,   Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 1,   Cyt‑c↓, 1,   iNOS↓, 2,   JNK↓, 1,   MAPK↓, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,  

DNA Damage & Repair ⓘ

PARP↓, 1,   PCNA↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,   HDAC↓, 1,   PI3K↓, 1,   PTEN↑, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   VEGF↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 5,   COX2∅, 1,   IFN-γ↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL2↓, 1,   Inflam↓, 7,   NF-kB↓, 5,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BDNF↑, 1,   TrkB↑, 1,  

Hormonal & Nuclear Receptors ⓘ

GR↓, 1,   GR↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   P450↓, 1,  

Clinical Biomarkers ⓘ

AST↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 3,   cardioP⇅, 1,   chemoPv↑, 3,   cognitive↑, 2,   hepatoP↑, 5,   memory↑, 3,   neuroP↓, 1,   neuroP↑, 4,   RenoP↑, 2,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 72

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:61  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page